Cancer Research and Treatment

A Case of Paratesticular Leiomyosarcoma Successfully Treated with Orchiectomy and Chemotherapy: Bong Suk Ko, Nae Yu Kim, Ah Jung Ryu, Dong Soon Kim, Soo Jung Gong, Dae Kyung Kim, Hyun Jin Son, Jung-Ae Lee; Cancer Res Treat. 2012;44(3):210-214. Published online September 30, 2012; DOI: https://doi.org/10.4143/crt.2012.44.3.210

A 50-year-old male patient presented with a right scrotal mass that had been growing rapidly for more than one year. A heterogeneous enhancing right scrotal mass (12x9 cm) with para-aortic and peri-caval lymphadenopathies was found on abdominal computed tomography (CT). Right orchiectomy was performed and the gross finding had shown intact testis with a well-defined, huge, whitish solid mass adjacent to the testis. According to pathology, the mass was characterized as a leiomyosarcoma, grade 3 (by National Cancer Instituted [NCI] system). Therefore, the diagnosis was stage III, grade 3 paratesticular leiomyosarcoma. The patient underwent additional systemic chemotherapy using ifosfamide and adriamycin. After nine cycles of chemotherapy, positron emission tomography-CT was performed and no FDP uptake was observed. The patient has been followed up for 12 months after systemic chemotherapy, and he has maintained a complete response. We report here on a rare case of paratesticular leiomyosarcoma treated successfully with orichiectomy and additional systemic chemotherapy.

Citations

Citations to this article as recorded by

Para-testicular Sarcoma: An Extreme Rarity
Anurag Mishra, Tridibes Mandal
Journal of Medical Evidence.2024;[Epub] CrossRef
Scrotal wall leiomyosarcoma: a case report and review of the literature
Zahra Erfani, Aileen Azari-yam, Seyed Reza Yahyazadeh
Journal of Medical Case Reports.2021;[Epub] CrossRef
Commentary on “A Case of Paratesticular Leiomyosarcoma Successfully Treated with Orchiectomy and Chemotherapy”
Edoardo Virgilio, Stefania Uccini, Paolo Marchetti, Paolo Mercantini
Cancer Research and Treatment.2016; 48(1): 422. CrossRef
Adult Urological Soft Tissue Sarcomas: A Multicenter Study of the Anatolian Society of Medical Oncology (ASMO)
Olcun Umit Unal, Ilhan Oztop, Serkan Menekse, Zuhat Urakci, Oktay Bozkurt, Melike Ozcelik, Yusuf Gunaydin, Nurgul Yasar, Dogan Yazilitas, Hilmi Kodaz, Burcu Yapar Taskoylu, Asude Aksoy, Umut Demirci, Murat Araz, Onder Tonyali, Alper Sevinc, Ahmet Ugur Yil
Asian Pacific Journal of Cancer Prevention.2015; 16(11): 4777. CrossRef
A Rare Case of Paratesticular Leiomyosarcoma
Shankar Haran, Vikram Balakrishan, Greg Neerhut
Case Reports in Urology.2014; 2014: 1. CrossRef

16,572 View
70 Download
5 Crossref

A Case of Synchronous Double Primary Cancer of the Penis and Urinary Bladder: Yong Soo Cho, Jung-Ae Lee, Si Bum Kim, Soo Jung Gong, Joo Heon Kim, Seon Min Youn, Eun Tak Kim; Cancer Res Treat. 2010;42(1):53-56. Published online March 31, 2010; DOI: https://doi.org/10.4143/crt.2010.42.1.53

Abstract PDF PubReader ePub

Multiple primary cancers are the occurrence of more than two cancers of different origin in an individual. Penile cancer is a rare disease, and finding it combined with other cancers is even rarer. A 64-year-old man with a painful penile mass was referred to us from a primary urological clinic. We performed a biopsy of the penile mass and the histology revealed a well-differentiated squamous cell carcinoma. Abdominal computed tomography showed a localized bladder tumor with inguinal lymphadenopathy. The patient underwent a partial penectomy, transurethral resection of the bladder tumor and inguinal lymph node dissection. The histology of the bladder tumor was high-grade papillary carcinoma, and that of the lymph node was squamous cell carcinoma. The penile and bladder tumors were in stage II (T1N1M0) and stage I (T1N0M0), respectively. We successfully treated the patient with adjuvant radiotherapy and systemic chemotherapy.

Citations

Citations to this article as recorded by

A rare case report of synchronous renal cell carcinoma and penile carcinoma
Indra Prakash Mandal, Krishnendu Maiti, Debansu Sarkar
Annals of Medical Science & Research.2025; 4(2): 108. CrossRef
Synchronous Double Primary Cancer of the Penisand Urinary Bladder
Deora H
MOJ Surgery.2017;[Epub] CrossRef

9,894 View
93 Download
2 Crossref

Randomized, Multi-center Phase II Trial of Docetaxel Plus Cisplatin Versus Etoposide Plus Cisplatin as the First-line Therapy for Patients with Advanced Non-Small Cell Lung Cancer: Nam-Su Lee, Hee-Sook Park, Jong-Ho Won, Dae-Sik Hong, Su-Taek Uh, Sang-Jae Lee, Joo-Hang Kim, Se-Kyu Kim, Myung-Ju Ahn, Jung-Hye Choi, Suk-Chul Yang, Jung-Ae Lee, Keun-Seok Lee, Chang-Yeol Yim, Yong-Chul Lee, Chul-Soo Kim, Moon-Hee Lee, Kab-Do Jung, Hanlim Moon, Yl-Sub Lee; Cancer Res Treat. 2005;37(6):332-338. Published online December 31, 2005; DOI: https://doi.org/10.4143/crt.2005.37.6.332

Abstract PDF PubReader ePub

Purpose

We prospectively conducted a multi-center, open-label, randomized phase II trial to compare the efficacy and safety of docetaxel plus cisplatin (DC) and etoposide plus cisplatin (EC) for treating advanced stage non-small cell lung cancer (NSCLC).

Materials and Methods

Seventy-eight previously untreated patients with locally advanced, recurrent or metastatic NSCLC were enrolled in this study. The patients received cisplatin 75 mg/m² on day 1 and either docetaxel 75 mg/m² on day 1 or etoposide 100 mg/m² on days 1 to 3 in the DC or EC arm, respectively, every 3 weeks.

Results

The objective response rate was 39.4% (15/38) and 18.4% (7/38) (p=0.023) in the DC and EC arms, respectively. The median time to progression (TTP) was 5.9 and 2.7 months (p=0.119), and the overall survival was 12.1 and 8.7 months (p=0.168) in the DC and EC arms, respectively. The prognostic factors for longer survival were an earlier disease stage (stage III, p=0.0095), the responders to DC (p=0.0174) and the adenocarcinoma histology (p=0.0454). The grades 3 and 4 toxicities were similar in both arms, with more febrile neutropenia (7.9% vs. 0%) and fatigue (7.9% vs. 0%) being noted in the DC arm.

Conclusion

DC offered a superior overall response rate than does EC, along with tolerable toxicity profiles, although the DC drug combination did not show significantly improved survival and TTP.

Citations

Citations to this article as recorded by

Correlations between objective response rate and survival-based endpoints in first-line advanced non-small cell lung Cancer: A systematic review and meta-analysis
Sarah Goring, Nebibe Varol, Nathalie Waser, Evan Popoff, Greta Lozano-Ortega, Adam Lee, Yong Yuan, Laura Eccles, Phuong Tran, John R. Penrod
Lung Cancer.2022; 170: 122. CrossRef

10,030 View
67 Download
1 Crossref

Search